Evaluation of Transcranial Photobiomodulation in Autism - Tolga Atilla Ceranoglu, MD @Synchrony2021

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by variable presentation of difficulties with socialization, reciprocal communication, and restrictive/repetitive behaviors. Currently, there exists no approved treatments for core features of ASD.
Transcranial Photobiomodulation (tPBM) is a novel treatment approach based on application of an invisible, non-ionizing electromagnetic wave that results in metabolic modulation in tissues targeted. A recent, prospective, 8-week open-label treatment trial in adult patients with ASD revealed that tPBM was well tolerated and was effective in reducing symptom severity of ASD. In addition, tPBM treatment was associated with improvements in executive functions.
Presently, an 8-week, prospective, placebo (sham) controlled, double-blind randomized clinical trial to evaluate the efficacy, safety, and tolerability of tPBM with near-infrared light in intellectually capable adults with ASD is underway. Up to 36 participants will be randomized at 1:1 ratio to receive daily tPBM or sham treatments for 8 weeks. The participants will be assessed on measures of efficacy and safety at regular scheduled visits throughout the study. A responder will be defined as those with a ≥25% reduction in Social Responsiveness Scale-2nd Edition, and a score of 2 or 1 on the Clinical Global Impression of ASD Improvement Subscale.
Tolga Atilla Ceranoglu, MD, received his medical degree from Marmara University School of Medicine, in Istanbul, Turkey. He then completed his psychiatry training at Brockton VA Medical Center and child psychiatry at Massachusetts General Hospital. He currently serves as Director of Psychiatry Service at Shriners Hospitals for Children, Boston and is staffed at MGH Bressler Program for Autism and Pediatric Psychopharmacology.
Dr. Ceranoglu’s research focuses on novel treatments of Autism Spectrum Disorders across the life span. His current treatment study focuses on use of near infrared LED light to improve core features associated with ASD, including social cognition and executive function deficits.
Dr. Ceranoglu also focuses on psychiatric disorders and long term outcomes among children who experienced severe burn injuries. Dr. Ceranoglu is a member of the Media Committee of American Academy of Child and Adolescent Psychiatry and regularly presents at national meetings on the psychological effects of media use among individuals with Autism Spectrum Disorders.
#neuromodulation #treatments #psychiatry #psychiatric #therapies #transcranial
🎥 This talk was part of Synchrony 2021 Online Symposium - 'From Bench to Biopharma', organised by the The BRAIN Foundation in partnership with UC Davis MIND Institute and CalTech.
🎥 For more Synchrony 2021 talks and highlights:
• Synchrony Symposium 20...
🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠
Synchrony synchronysympo... is the first and only international symposium on translational research in #autism, that brings together academia, #biotech, pharmaceutical companies and #venture partners from around the world with the mission to improve health and quality of life of people with #autismspectrumdisorder.
🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠
The BRAIN Foundation brainfoundatio... is a 501c(3) non-profit. The founders of BRAIN envision a world where every child and adult on the autism spectrum is healthy, participates fully in education and employment, and has a better quality of life. It aims to catalyze research that results in evidence-based interventions for the disabilities associated with autism, and also results in better medical standard of care.
To accomplish this, it funds impactful research through #philanthropy and our network of partners in the venture, corporate, and grassroots community.